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Summary
Objective: The STR/ort mouse develops a naturally occurring osteoarthritis of the femorotibial joint that provides a model with which to
establish the time course of biochemical changes taking place in articular cartilage in the disease. Our objective was to define the onset,
location and progression of type II collagen cleavage by collagenase in the tibial cartilage of the STR/ort mouse. For comparison, cartilage
collagen cleavage was also studied in collagen-induced arthritis in DBA mice.
Design: STR and control CBA mice aged 6–45 weeks were examined. DBA/1 mice were studied 2 and 3 weeks after initiating
collagen-induced arthritis. Collagen cleavage was detected by immunolocalization using the antibody COL2-3/4Cshort which recognizes a
carboxy terminal neoepitope created by collagenase cleavage of type I and II collagens.
Results: No COL 2-3/4Cshort immunostaining was observed in the intact cartilage of healthy young or old mice. The earliest detectable
collagen degradation occurred at the cartilage surface coincident with the appearance of surface roughening. As fibrillations developed,
further collagen degradation was evident around the edge of the lesion and in adjacent extracellular matrix. In contrast, staining was
observed throughout the cartilage matrix in type II collagen-induced arthritis prior to the development of histopathological lesions.
Conclusion: No evidence was found for collagen cleavage in intact/pre-lesional cartilage from STR/ort mice. Local collagen cleavage was,
however, clearly associated with very early histopathological lesions and immunostaining with COL 2-3/4Cshort increased with progression
of the latter. In contrast, type II collagen cleavage occurs throughout the articular cartilage at an early stage in collagen-induced arthritis.
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The breakdown of articular cartilage is an important feature
of both osteoarthritis (OA) and rheumatoid arthritis (RA).
Type II collagen is the characteristic fibrillar collagen
of articular cartilage and is one of the main macromolecu-
lar components of its extracellular matrix. It forms a fibrillar
network throughout the extracellular matrix of articular
cartilage and provides tensile strength by resisting the
swelling pressure resulting from the hydration of the
highly negatively charged proteoglycan aggregates within
the matrix1. The proteolytic cleavage of type II collagen
is thought to be one of the key steps involved in
cartilage breakdown during arthritis2–4. There is a very172limited turnover of type II collagen in mature cartilage5 so
cleavage is likely to be a critical step resulting in the
irreversible loss of cartilage structural integrity.
Cleavage of type II collagen during arthritis is thought to
be carried out mainly by the matrix metalloproteinase
(MMP) enzymes, particularly the collagenases; interstitial
collagenase (MMP-1), neutrophil collagenase (MMP-8) and
collagenase-3 (MMP-13) which can all be produced by
chondrocytes6,7. The collagenases cleave within the triple
helical region of fibrillar collagens resulting in characteristic
one-quarter and three-quarter fragments4. Antineoepitope
antibodies have been produced to recognize the cleaved
ends of these collagen fragments, permitting their detection
and measurement4. Type II collagen breakdown in OA
appears to involve collagenase-38. Reports that gelatinase
A (MMP-2) has collagenolytic activity (on type I collagen)9
have been contradicted by others10. Membrane type 1
metalloproteinase (MT1-MMP; MMP-14)11 and cathepsin
K12 also have collagenolytic activity although their role, if
any, in type II collagen breakdown in arthritis is unclear.
Previous evidence has shown that there is both a loss of
type II collagen and an increase in denatured type II
collagen during late stage human OA2,13. Furthermore,
Billinghurst et al.4 reported enhanced cleavage of type II
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ANIMALS
Twenty-three male STR/ort mice aged 6–45 weeks from
the Imperial College inbred STR/ort colony were examined
along with 12 age- and sex-matched CBA control mice
(from Charles River, U.K.). Ten DBA/1 male mice (from
Charles River, France) with CIA together with 10 age- and
sex-matched control DBA/1 mice were examined for com-
parison. Animals had access to standard diet and water ad
libitum. Animal husbandry and experiments were carried
out under authority of national and local licences.INDUCTION OF COLLAGEN-INDUCED ARTHRITIS
Nine- to ten-week old DBA/1 mice were randomly
assigned to four groups of five animals each (CIA 2 and 3
weeks post-induction, controls for 2 and 3 week CIA
groups). CIA mice were sensitized at the base of the tailwith 100 l of a mixture consisting of 4 mg/ml of chicken
type II collagen emulsified in an equal volume of complete
Freund’s adjuvant (strain H37Ra; Difco, U.S.A.)21. Type II
collagen (a generous gift of M. Huc, Coletica, France) had
been purified from normal chicken sternal cartilage and
was dissolved overnight with 0.1 M acetic acid to a concen-
tration of 4 mg/ml at 4°C with mild agitation. Twenty-one
days later, arthritis was induced by injecting mice intra-
peritoneally with 200 g of chicken type II collagen in
phosphate buffered saline (PBS; 0.5 ml/mouse). In order to
boost the arthritic process, mice received 40 g of bacterial
lipopolysaccharide from Escherichia coli (strain B55:b5;
Difco, U.S.A.)22. All CIA and control animals were exam-
ined after sacrifice by cardiac puncture under isoflurane
anaesthesia ForeneR, Abbott, France) either 2 or 3 weeks
after arthritis induction.HISTOLOGY AND GRADING OF CARTILAGE LESIONS
STR/ort mice were killed by cervical dislocation. For all
mice, the skin was removed from the legs and the knee
joints dissected out with the associated muscle. Knee joints
were dipped briefly in a 5% aqueous solution of polyvinyl
alcohol and then snap frozen at −70°C in n-hexane (BDH
Laboratories, Poole, U.K.). Joints were stored at −70°C
until sectioned. Serial sections of 10 m were cut in an
anterior to posterior direction using a Bright’s bone cutting
cryostat. The sections were mounted onto polylysine
coated slides (BDH) and stored at −70°C until use.
Unstained sections were graded for histological OA
changes using the grading system reported previously23;
0=no change; 1=roughened articular surface and small
fibrillations; 2=fibrillations down to zone 2 (chondrocytes
just below the surface spindle cells) and some loss of
surface lamina; 3=loss of surface lamina and fibrillations
extending down to the calcified cartilage; 4=major fibrilla-
tions and cartilage erosion down to subchondral bone;
5=major fibrillations and erosion of up to 80% of cartilage;
6=greater than 80% loss of cartilage. Each section was
graded and the overall grade of damage to the whole joint
was defined as the most severe grade observed within all
sections of that joint.DETECTION OF TYPE II COLLAGEN DEGRADATION
Type II collagen degradation was visualized with the
rabbit polyclonal antibody COL2-3/4Cshort, using a modifi-
cation of the previous method4. Briefly, thawed sections
were fixed with freshly prepared 4% paraformaldehyde
(BDH) in PBS for 5 min at room temperature and then
rinsed extensively with PBS. In order to enhance the
permeability of the extracellular matrix, sections were
treated with 0.5% testicular hyaluronidase (type I–IV,
EC.3.2.1.35; Sigma) in PBS for 30 min at 37°C. Sections
were washed and any endogenous peroxidase activity was
blocked using 1% v/v hydrogen peroxide (BDH) in absolute
ethanol for 30 min at room temperature. Sections were
washed and non-specific staining was blocked by incu-
bation with 10% normal swine serum (Dako, Denmark) in
PBS with 1% bovine serum albumin (PBS-BSA; Sigma).
Sections were incubated overnight with COL2-3/4Cshort(1:800 dilution) in PBS-BSA at 4°C in a humidified chamber.
Negative control sections were incubated with COL2-3/
4Cshort that had been preabsorbed with 500 g/ml of the
immunizing peptide for 1 h at 37°C. In some cases APMAcollagen by collagenases in human OA. Similarly, using in
situ zymography, Freemont et al. showed that type II
collagen degrading activity varies with cartilage lesions and
co-distributes with MMP-13 in human OA14. Stoop and
colleagues investigated collagen degradation in spon-
taneous OA in cartilages from the femorotibial joint of aged
C57B1/6 and BALB/c mice and found that it was present
at sites of degradation15. However, it remains unclear
whether type II collagen degradation is an early or late
event in the pathobiology of OA. Most studies have been
carried out on human arthritic tissue from late stage dis-
ease (i.e. following joint replacement) or in explant culture
systems that cannot relate type II collagen degradation with
the clinical progression of OA. From a therapeutic point of
view it is important to determine the time course and
pattern of collagen degradation during the disease process
and its relation to cartilage changes.
There is some evidence to suggest that collagen degra-
dation may occur at an early time-point in the OA disease
process. Early events in OA include the loss of cartilage
tensile strength and swelling from an increase in water in
the matrix, indicative of damage to the collagen net-
work16,17 One way in which early (i.e. pre-lesional) and late
changes in cartilage can be monitored during arthritis
is by the use of animal models. The STR/ort mouse is a
naturally occurring model for OA of the human knee18.
Male STR/ort mice develop histopathological lesions in the
medial tibial plateau which are similar in severity and rate of
progression to those in the human disease19. Around
85% of male mice develop such lesions by 35 weeks of
age18. Type II collagen cleavage has not been studied
previously in this model, although aggrecan cleavage by
matrix metalloproteinases and aggrecanases has been
described20.
In this study we used the antibody COL 2-3/4Cshort which
recognizes a carboxyterminal neoepitope on the three-
quarter fragment generated by collagenase cleavage of
type I and II collagens4, to determine how collagen degra-
dation in cartilage is related to the development of OA
lesions in the STR/ort model. Young and mature mice were
investigated at all stages of the disease. Collagen cleavage
by collagenase in articular cartilage from mice with murine
type II collagen-induced-arthritis (CIA), a severe inflamma-
tory model with rapid cartilage damage similar to human
RA, was examined for comparison.
174 J. S. Price et al.: Collagen cleavage in STR/ort mouse cartilageactivated human recombinant proMMP-13 (20 g/ml; a
kind gift from Professor G. Murphy, School of Biological
Sciences, University of East Anglia, Norwich) was added to
the sections (20 min at 37°C) prior to incubation with
COL2-3/4Cshort to provide a positive control for the anti-
body. Unbound COL2-3/4Cshort antibody was removed by
washing in PBS (3×5 min at room temperature) and bound
antibody was detected using a biotin labelled swine anti-
rabbit IgG secondary antibody for 1 h at room temperature
(1:400 dilution; Dako). The bound secondary antibody was
detected with a biotin-streptavidin detection system (Vector
ABC reagent; Vector Laboratories, Peterborough, U.K.).
The peroxidase was detected using a DAB detection kit
(Vector Laboratories) according to the manufacturers
instructions. After rinsing, sections were air dried and
mounted with aquamount (BDH). Staining was recorded as
either being present (+) or absent (−) at two locations, the
articular surface and the extracellular matrix of the tibial
cartilage.DETECTION OF PROTEOGLYCAN DEGRADATION
Sections were stained as described previously20 for
the VDIPEN and NITEGE neoepitopes, indicative of cleav-
age of the core protein of aggrecan by MMPs and aggre-
canases, respectively. Proteoglycan glycosaminoglycan
side chains were stained using the Alcian Blue method24.DETECTION OF INFLAMMATORY MACROPHAGES IN
COLLAGEN-INDUCED ARTHRITIS (CIA)
Inflammation in the CIA joints was assessed using a
murine macrophage marker (rat anti-mouse F4/80 antigen;
Serotec, Oxford, U.K.). Briefly, sections were fixed in 4%
paraformaldehyde in PBS, washed in PBS then blocked
using 5% normal rabbit serum for 30 min at 37°C. Sections
were then incubated with the primary antibody, rat anti-
mouse F4/80 antigen for 1 h at 37°C (1:50 dilution).
Anti-F4/80 antibody binding was detected using a bio-
tinylated rabbit anti-rat IgG (H+L) mouse absorbed second-
ary antibody (1:100 dilution; Vector) for 1 h at 37°C. The
antibody was detected using a streptavidin-FITC antibody
(1:200; Vector) for 30 min at 37°C. After rinsing, sections
were air dried and mounted with fluorescent mounting
medium containing propridium iodide to distinguish the cell
nuclei (Vector).ResultsTable I
Histological grading and presence of collagen degradation in the
STR/ort model of OA
Histology
grade
Age
(weeks)
COL2-3/4Cshort staining
Articular
surface
Extracellular
matrix
0 6 − −
0 12 − −
0 13 − −
0 13 − −
0 20 − −
0 22 − −
0 24 − −
0 30 − −
1 14 + −
1 20 + −
1 22 + −
1 33 − +
2 18 − +
2 20 + +
2 24 + +
3 24 − +
3 30 − +
3 33 − +
4 12 − +
4 22 − +
4 24 − +
4 45 − +
5 22 − +
The medial tibial cartilage of STR/ort mice of different ages was
graded for osteoarthritic lesions using the scale described in the
Methods section. Type II collagen degradation was visualized by
immunostaining using antibody COL2-3/4Cshort and was seen at
the articular surface and/or in the extracellular matrix adjacent to
lesions. (+), Positive immunostaining for collagen degradation;
(−), no staining.TYPE II COLLAGEN DEGRADATION IN THE STR/ORT MODEL OF OA
STR/ort mice with no articular cartilage damage and
with osteoarthritic changes ranging from grade 1 (surface
roughening and small fibrillations) to grade 5 (up to 80%
loss of cartilage) were examined (Table I). Type II
collagen degradation was observed in all mice which had
histological lesions, including those with grade 1.
A very narrow zone of immunostaining was present on
the surface of articular cartilages from the medial tibial
plateau in regions where surface roughening occurred [Fig.
1(a)]. This was a consistent finding but was not evident in
cartilages with a smooth surface (see below). In cartilage
with the next stage of histopathological damage [grade 2;
Fig. 1(b)], immunostaining was present along the fibrillated
edge of the lesion, and along the surface of the articularcartilage adjacent to the lesion. With progression to more
severe grades of arthritis [e.g. grade 4; Fig. 1(c)] marked
type II collagen degradation was evident at the site of the
lesion itself and also less strongly in the surrounding
extracellular matrix. We investigated the specificity of
COL2-3/4Cshort immunostaining by pre-absorbing the anti-
body with its immunizing peptide before adding it to the
sections. This resulted in little or no immunostaining, even
in severely damaged cartilage [e.g. grade 4 lesion; Fig.
1(d)], indicating specificity of the COL2-3/4Cshort antibody
for collagenase-generated collagen fragments.
STR/ort mice usually develop lesions on the medial side
of the tibial plateau18 and the results shown in Table I and
Fig. 1 are for the medial side of the joint. The lateral
compartment of the joint develops lesions much less
frequently and often at a later stage of the disease18.
However, when lesions were present in the lateral cartilage
they also showed evidence of type II collagen degradation
(results not shown).
There was no consistent evidence of type II collagen
degradation in histologically normal cartilage of either
young or old STR/ort mice [Table I, Fig. 2(a),(b)), although
occasional faint staining was observed in a pericellular
location around chondrocytes in young intact cartilage
which was not present in antigen peptide absorbed controls
(not shown). Moreover, control age-matched CBA mice, all
of which had histologically normal cartilage, showed no
evidence of type II collagen degradation in either young or
old animals [Fig. 2(c)]. This was not the case for cartilage
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collagen degradation could be detected in intact normal
articular cartilage of either CBA or STR/ort mice [Fig. 2(d)].
Immunostaining occurred throughout the cartilage matrix in
these sections, indicating that collagen cleavage can be
detected readily with the antibody, where present.COMPARISON WITH TYPE II COLLAGEN DEGRADATION DURING
COLLAGEN-INDUCED-ARTHRITIS (CIA)
CIA is an inflammatory arthritis similar to RA and is
associated with rapid onset of damage to articular carti-
lage25, including marked collagen degradation15. It was of
interest therefore to compare the pattern of collagen cleav-
age in this disease with that in spontaneous OA of STR/ort
mice. The results of the CIA experiments are summarized
in Table II. Only one-third of the mice induced developed
the characteristic synovial inflammatory changes associ-
ated with CIA, as detected with the antibody to the macro-
phage marker F4/80. This low incidence of inflammatory
arthritis could have been due to the use of chicken type II
collagen for the induction. The use of bovine collagen was
banned at the time of the experiment because of the bovine
spongiform encephalitis crisis in the U.K. Collagen degra-
dation was not observed in age-matched non-induced
DBA/1 control joints (Table II). Similarly, it did not occur
frequently in joints of induced mice lacking signs of inflam-
mation [Table II; Fig. 3(a)]. In two joints that showed weak
immunostaining for collagen degradation there was no
inflammation in the knee joint studied, as determined
by F4/80 antigen staining, but there was evidence for
inflammation in the contralateral knee joint (not shown).
However, when joints showed clear histological signs of
inflammation, there was marked type II collagen degrada-
tion (Table II). Moreover, the extent of degradation wasmore generalized than in the STR/ort joints and occurred
throughout the cartilage extracellular matrix [e.g. Fig. 3(b)].
Strong immunostaining was observed in these inflamed
joints even when there was little evidence of histological
damage to the cartilage (Table II). Furthermore, in contrast
to the focal areas of collagen cleavage associated with
STR/ort osteoarthritic lesions, CIA joints with histological
damage showed COL2-3/4Cshort staining in areas of thejoint distant from the lesion with an intact articular cartilage
surface. The immunostaining was markedly reduced in
sections from CIA mice by preabsorption of the antibody
with its peptide, demonstrating its specificity [Fig. 3(c)].
CIA joints with severe inflammation showed a general-
ized loss of Alcian Blue staining throughout the cartilage
matrix accompanied by a large increase in the aggrecan
cleavage neoepitopes VDIPEN and NITEGE26,27 (not
shown). Thus widespread enhanced proteoglycan cleav-
age occurred simultaneously with collagen cleavage in
articular cartilage in this model from an early stage of the
disease process. This contrasts with the pattern of
increased loss of proteoglycan in developing OA in the tibial
cartilage of STR/ort mice which occurs in more focal areas
associated with lesion development18,20.Fig. 1. Type II collagen degradation in STR/ort tibial cartilage is associated with cartilage damage. Antibody COL2-3/4Cshort was used to
detect the collagenase-generated fragments of type II collagen in medial tibial cartilage with histological lesions of OA of varying severity.
Lesions were graded as described in the Methods section. Type II collagen degradation is present: (a), along the surface of roughened
cartilage (grade 1); (b), in the lesional area of a mild lesion (grade 2); (c), in the lesional area of severe damage (grade 4). (d) Pre-absorption
of COL2-3/4Cshort with its immunizing peptide resulted in complete loss of staining even in severely damaged regions (grade 4). T—tibia;
AC—tibial articular cartilage. Original magnification, ×50.Discussion
Our findings indicate that the level of type II collagen
degradation in vivo in normal articular cartilage in mice
aged 6 weeks or older is either non-existent, or so low as to
be undetectable by immunohistochemistry with the COL2-
3/4Cshort antibody. Since the immunohistochemical method
was able to detect very discrete changes in the appearance
of the COL2-3/4Cshort neoepitope at the surface of STR/ort
cartilage with minimal histopathological change [e.g. Fig.
176 J. S. Price et al.: Collagen cleavage in STR/ort mouse cartilageFig. 2. Lack of type II collagen degradation in undamaged murine tibial cartilage. Antibody COL2-3/4Cshort was used to detect the
collagenase-generated fragments of type II collagen in undamaged medial tibial cartilage of mice of different ages. (a), 6 week STR/ort; (b),
33-week STR/ort; (c), 35-week CBA control. No staining was observed in undamaged cartilage from either old or young CBA or STR/ort mice.
Type II collagen degradation could be induced throughout the matrix of normal cartilage of either STR/ort or CBA mice by prior digestion of
the section with MMP-13. (d) 12-week STR/ort digested with MMP-13. T—tibia; AC—tibial articular cartilage. Original magnification, ×50.Table II
Histologic grading, inflammatory changes and the presence of
collagen degradation in DBA/1 mice with CIA
Histological
grade
Weeks
post-CIA
Joint
type
COL2-3/4Cshort
staining
in matrix
Inflammation
0 2 Control − −
0 3 Control − −
0 2 CIA − −
0 3 CIA − −
0 2 CIA + −
1 2 CIA − −
1 3 CIA − −
1 3 CIA + + + +
2 3 CIA + + + +
3 2 CIA + + + +
Arthritic lesions in the medial tibial cartilage were graded histo-
logically according to the scale described in the Methods section.
Type II collagen degradation was visualized by immunostaining
using antibody COL2-3/4Cshort and, where present, was seen
throughout the articular cartilage matrix. Inflammatory changes
were assessed by positive staining for a macrophage marker
(murine F4/80 antigen): (−), no staining; (+), weak staining; (+ +),
strong staining. Control, non-induced DBA/1 mice; CIA, mice with
collagen-induced arthritis.1(a)], it appears to be a sensitive method for detecting
collagen cleavage in vivo.
Secondly, the study shows that collagenases degrade
type II collagen during the development of spontaneous OA
in STR/ort mice, but with a quite different pattern of activity
to that occurring in murine CIA-arthritis. In the STR/ort
model type II collagen cleavage is restricted to cartilage in
the area of histopathological lesions. Even aged STR/ort
mice with type II collagen cleavage in damaged areas of
cartilage show no evidence of such degradation in regionsof non-lesional cartilage. Thus, collagen degradation is a
very localized event in spontaneous OA in STR/ort mice
and is specifically associated with histopathological
lesions. In contrast, type II collagen cleavage in the inflam-
matory CIA model is a much more generalized process,
with rapid onset of collagen degradation occurring through-
out the cartilage even before histopathological lesions
appear, and in intact regions of the cartilage distant from
the lesions.
Our results indicate that collagen degradation begins at
the surface of the cartilage in the superficial zone in
spontaneous OA in STR/ort mice and is restricted to focal
sites where the cartilage is damaged. This is a very similar
pattern of type II collagen degradation to that reported
recently in spontaneous OA in very old C57Bl/6 and
BALB/c mice15. In human OA, although the initial damage
to type II collagen occurs in the superficial and upper mid
zones, it later extends to the deeper zones of the cartilage
and is more pronounced3. Nevertheless, recent studies on
human OA also revealed evidence for very focal damage to
type II collagen that is also associated with lesions (Webb
et al., manuscript in preparation).
An obvious candidate enzyme for collagen breakdown in
the STR/ort model is MMP-13 as, so far, this is the only
collagenase shown to be present in mouse tissue28. In situ
hybridization experiments indicate an abundance of mRNA
for MMP-13 in STR/ort mouse tibial cartilage compared to
levels in CBA control mice. However, these transcripts
occur predominantly in the chondrocytes of the mid and
deep zones and are present before any sign of cartilage
damage is evident. Moreover, there is a marked decrease
in MMP-13 transcripts in chondrocytes in the vicinity of
lesions and we found no immunohistochemical evidence
for MMP-13 protein at these sites in STR/ort cartilage at
any stage29. Thus the observed expression pattern of
MMP-13 does not fit well with the mapping of the type II
collagen cleavage sites in STR/ort tibial cartilage.
Osteoarthritis and Cartilage Vol. 10, No. 3 177Fig. 3. Type II collagen degradation in murine collagen-induced
arthritis. Antibody COL2-3/4Cshort was used to detect the
collagenase-generated fragments of type II collagen in the carti-
lage of the medial tibial plateau of DBA mice with collagen-
induced-arthritis. (a) No type II collagen degradation was observed
in collagen-induced mice free of inflammation. (b) Type II collagen
degradation was observed throughout the matrix of the inflamed
joints, both when lesions were present and when the cartilage
appeared intact. (c) Pre-absorption of COL2-3/4Cshort with its
immunizing peptide resulted in a marked reduction of this staining.
T—tibia; AC—tibial articular cartilage. Original magnification, ×50.More recently other enzymes have been described as
having collagenolytic activity such as gelatinase A9, MT1-
MMP11 and cathepsin K12 and are thus candidates for type
II collagen cleavage in STR/ort cartilage. Gelatinase A
(MMP-2) is reported to cleave type I collagen at the same
site as interstitial collagenases9, although other groups
disagree with this finding (Mort et al., unpublished obser-
vations). We found that MMP-2 mRNA and MT1-MMP
mRNA and protein is expressed throughout the STR/ort
tibial cartilage. However, the MT1-MMP is expressed at
similar levels in CBA cartilage and expression decreases in
chondrocytes near lesions in STR/ort cartilage, which does
not support a role for this enzyme in type II collagen
degradation at such sites29. The cysteine protease
Cathepsin K is also capable of cleaving type II collagen.
However, this cleavage is thought to occur in the N terminalhelical domain at a site distinct from the collagenase
cleavage site12.
In this study we looked specifically at the role of colla-
genases in the development of OA in STR/ort mice, albeit
indirectly through the products of collagenase activity in the
tibial cartilage. Although the COL2-3/4Cshort antibody we
used specifically recognizes the C-terminus of a collagen
fragment generated by collagenase cleavage at a point
three-quarters of the way along the collagen molecule, we
cannot rule out the possibility that other enzymes are able
to produce this fragment. Similarly, it is possible that the
amount of type II collagen degradation is being underesti-
mated due to enzymes acting at a different site on type II
collagen that this antibody cannot recognize. Furthermore,
enzymatic processing of the fragments produced by colla-
genases can result in the loss of the neoepitope following
its cleavage by gelatinase A,B and stromelysin (Poole
et al., unpublished observations) and removal by second-
ary cleavage of the -chain releasing the epitope from the
cartilage8,30.
There is evidence from previous studies in the STR/ort
murine model that biochemical changes occur in the STR/
ort cartilage before any lesions have developed. The
expression of cytokines such as IL-1/, IL-6, TGF and
IGF is up-regulated in STR/ort cartilage before lesions
develop, whereas transcripts for these factors were not
detected in control CBA cartilage23. Total proteoglycan
levels in the STR/ort tibial cartilage also increase at an
early stage in disease and then decrease at a later stage31.
This initial increase followed by proteoglycan loss is a
characteristic feature of some other animal models of
OA and is thought to be due to an attempted repair
response32,33.
Levels of the MMP and aggrecanase generated aggre-
can cleavage neoepitopes26,27, VDIPEN and NITEGE
respectively, have been studied in the STR/ort model20.
Each neoepitope mapped to a separate location in the
prelesional stages of OA in the STR/ort cartilage. These
locations were the deep zone for VDIPEN and the upper
zone for NITEGE, the same as found in normal CBA
cartilage. However, with progression to OA lesions both
neoepitopes appear prominently at the site of the lesion.
Thus, as with the specific enzymes involved in collagen
degradation in the STR/ort model, proteases involved in
proteoglycan degradation appear to be produced and acti-
vated in focal areas associated with lesion development.
Interestingly, in antigen-induced arthritis, a less severe
inflammatory arthritis than CIA, it has been shown that
VDIPEN and COL2-3/4C staining co-localize, suggesting a
coupling of both cleavage activities34. However, in
collagen-induced arthritis, collagenase and proteoglycan
degrading enzymes appear to be induced throughout
articular cartilage. In two CIA mice there was evidence of
cartilage collagen cleavage before any histopathological
lesion was evident, suggesting that collagenases are active
in the tissue at a very early stage of the disease. In general,
cleavage of cartilage collagen in CIA mice coincides with
the appearance of inflammatory cells in the synovium,
suggesting that signals originating at this site induce
chondrocytic collagenase activity. We have rarely detected
inflammation in the knee joints of STR/ort mice in our
colony and when present it occurs in late stage disease and
is minimal. These differences in the mechanism of matrix
breakdown and disease progression in the two models
must be taken into account when using either to test new
therapies.
178 J. S. Price et al.: Collagen cleavage in STR/ort mouse cartilageThe data in the present report consolidate other reports
about the biochemical changes underlying the develop-
ment of OA in the tibial cartilage of STR/ort
mice18,20,23,29,31,35. Overall these provide the most com-
prehensive account to date of such changes in naturally
occurring OA in a small animal model.References
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